Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 17, 2021 | SVP Global Operations and R&D | Form 4 | Other acquisition or disposition | 8,116 | -- | 8,116 | |
| Jul 21, 2021 | SVP Global Operations and R&D | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,116 | -- | 8,116 | |
| Jan 19, 2010 | Director, President & CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 8,149 | $17.22 | 97,675 | |
| Jan 19, 2010 | President & CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 8,149 | $17.22 | 96,851 | |
| Aug 12, 2021 | SVP/GM, Vascular Access | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,210 | -- | 34,871 | |
| May 11, 2005 | Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,250 | -- | 8,250 | |
| Jun 22, 2018 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 8,319 | $22.77 | 52,655 | |
| Jul 07, 2022 | EVP and CFO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,357 | -- | -- | |
| Aug 12, 2021 | EVP and CFO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,357 | -- | -- | |
| Oct 16, 2019 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,357 | -- | 8,357 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.